1. Phylogeny  
ERBB2, also known as HER2, belongs to the ErbB family of receptor tyrosine kinases, a subgroup within the human kinome that also comprises EGFR (ERBB1), ErbB3 (HER3), and ErbB4 (HER4). Phylogenetic analyses indicate that these receptors share a common evolutionary origin that can be traced back to early metazoans, with subsequent gene duplication events giving rise to the diversity observed today (riese1998specificitywithinthe pages 2-4, pinet2021expandingthedisorderfunction pages 3-5). Within the ErbB clade, ERBB2 is unique in that, unlike its siblings, it does not possess a directly activatable ligand‐binding domain. Instead, its extracellular structure features a distinct insertion adjacent to the putative ligand‐binding interface that predisposes it to dimerize with other ligand‐bound ErbB receptors. This structural divergence is conserved across vertebrates, with ERBB2 orthologs displaying high sequence similarity in the intracellular kinase domain and regulatory C‐terminal tail, underscoring its essential role in signal transduction (riese1998specificitywithinthe pages 8-8, butti2018receptortyrosinekinases pages 17-18). As members of the receptor tyrosine kinase superfamily, the ErbB receptors—including ERBB2—form an integral part of the signaling networks that regulate cell proliferation, differentiation, and survival, and their conservation reflects these indispensable cellular functions (pinet2021expandingthedisorderfunction pages 3-5).

2. Reaction Catalyzed  
ERBB2 functions as a protein tyrosine kinase that catalyzes the transfer of a phosphate group from ATP to the hydroxyl group of tyrosine residues on specific substrate proteins. The chemical reaction can be summarized by the following equation:  
  ATP + [protein]‑(L‑tyrosine) → ADP + [protein]‑(L‑tyrosine‑phosphate) + H⁺  
This autophosphorylation reaction occurs on multiple tyrosine residues located within the receptor’s intracellular C‑terminal tail and is also involved in phosphorylating downstream adaptor proteins once the receptor is engaged in heterodimer formation (jr2004theerbbherreceptor pages 7-8, riese1998specificitywithinthe pages 8-8). Through this catalytic event, ERBB2 creates binding sites for proteins containing SH2 and PTB domains, thereby orchestrating the assembly of multi‐protein signaling complexes that activate critical pathways such as PI3K/AKT and Ras/MAPK.

3. Cofactor Requirements  
The kinase activity of ERBB2 is dependent on the presence of divalent cations, in particular Mg²⁺ ions, which serve as essential cofactors for the proper binding and positioning of ATP within the active site of the kinase domain. These Mg²⁺ ions coordinate with the phosphate groups of ATP, thereby facilitating the phosphoryl transfer to substrate tyrosine residues (jr2004theerbbherreceptor pages 7-8, riese1998specificitywithinthe pages 8-8).

4. Substrate Specificity  
ERBB2 exhibits substrate specificity that is characteristic of receptor tyrosine kinases. Its intrinsic catalytic activity is directed primarily toward tyrosine residues within its own C‑terminal tail, leading to autophosphorylation, as well as toward tyrosine residues on proteins recruited into the signaling complex upon receptor activation. Although a strict consensus sequence for ERBB2 substrates has not been definitively established, its substrate preference aligns with the general trend among tyrosine kinases where steric and electrostatic complementarity plays a role in target recognition. Following heterodimerization with ligand-bound ErbB receptors, ERBB2 phosphorylates critical tyrosine motifs that serve as docking sites for downstream signaling molecules and adaptor proteins, thereby linking receptor activation to pathways such as PI3K/AKT and Ras/MAPK (bose2006phosphoproteomicanalysisof pages 1-3, jr2004theerbbherreceptor pages 7-8).

5. Structure  
ERBB2 is a transmembrane receptor whose overall architecture is organized into several distinct domains that collaborate to mediate its function. The extracellular region is composed of four subdomains: two leucine-rich regions (domains I and III) that are involved in structuring the receptor and two cysteine-rich regions (domains II and IV) that contribute to dimerization. Unlike other family members, ERBB2 does not bind ligand directly; its extracellular structure is maintained in a conformation that is predisposed to heterodimerization with other ErbB receptors (jr2004theerbbherreceptor pages 1-2, pinet2021expandingthedisorderfunction pages 3-5).  
The receptor spans the plasma membrane via a single α‑helical transmembrane segment that plays a role not only in anchoring the receptor within the lipid bilayer but also in transmitting dimerization-induced conformational changes from the extracellular to the intracellular domain.  
The intracellular portion of ERBB2 houses a conserved tyrosine kinase domain divided into two lobes—the smaller N‑terminal lobe contains a glycine-rich loop critical for nucleotide binding, and the larger C‑terminal lobe supports substrate binding and catalysis. Within this kinase domain, key structural features such as the activation loop, the C‑helix, and the catalytic loop are present and contribute to the regulation of kinase activity. In ERBB2, the activation loop is arranged in a conformation that facilitates autophosphorylation upon receptor dimerization (jr2004theerbbherreceptor pages 4-5, collins2019preclinicalcharacteristicsof pages 5-7).  
Immediately following the catalytic domain is a C‑terminal tail that is intrinsically disordered; this region contains multiple autophosphorylation sites that, once phosphorylated, serve as docking sites for signaling proteins bearing SH2 or PTB domains. The disordered nature of the C‑terminal tail endows it with the flexibility to interact with a diverse array of adaptor proteins, thereby modulating downstream signaling events. Structural studies and computational models, including those based on AlphaFold predictions, support the notion that while the kinase domain retains a well‐defined three-dimensional structure, the C‑terminal tail remains flexible and functionally versatile (pinet2021expandingthedisorderfunction pages 9-11, collins2019preclinicalcharacteristicsof pages 21-22). In addition, the extracellular region of ERBB2 contains an exposed dimerization arm that, in the absence of a direct ligand, makes ERBB2 an ideal coreceptor for heterodimerization, ensuring effective propagation of mitogenic signals (collins2019preclinicalcharacteristicsof pages 2-5, pinet2021expandingthedisorderfunction pages 17-19).

6. Regulation  
The activity of ERBB2 is tightly regulated through several mechanisms that collectively ensure proper control of downstream signaling. One of the primary modes of regulation is receptor dimerization. In contrast to receptors that directly bind a ligand via their extracellular domain, ERBB2 lacks a specific ligand and is instead activated through heterodimer formation with other members of the ErbB family that do bind ligands, such as ErbB3. This heterodimerization triggers autophosphorylation of ERBB2 on multiple tyrosine residues within its C‑terminal tail, which creates binding sites for various signaling and adaptor proteins (butti2018receptortyrosinekinases pages 17-18, collins2019preclinicalcharacteristicsof pages 19-21).  
Post‐translational modifications, particularly phosphorylation, play an essential role in modulating receptor function. Upon dimerization, ERBB2 undergoes extensive autophosphorylation; these phosphorylated tyrosine residues serve as platforms for assembly of signaling complexes that drive oncogenic signaling. In addition, receptor ubiquitination by E3 ubiquitin ligases leads to internalization and degradation of ERBB2, serving as a negative regulatory mechanism to attenuate signal transduction and control receptor turnover (collins2019preclinicalcharacteristicsof pages 24-25, rochette2015anthracyclinestrastuzumabnewaspects pages 35-37).  
Multiple regulatory proteins further modulate ERBB2 activity. For example, chaperone proteins such as HSP90 stabilize the receptor and ensure its proper folding and trafficking. Disruption of the ERBB2–HSP90 interaction has been shown to promote receptor degradation. In addition, recent studies have identified modulatory interactions with proteins like prolidase (PEPD), which binds to ERBB2 and can induce receptor internalization along with a reduction in Src kinase association, thereby attenuating downstream signaling cascades (yang2014identificationofprolidase pages 6-7).  
Collectively, these regulatory events—a combination of dimerization‐dependent activation, autophosphorylation, subsequent recruitment of adaptor proteins, ubiquitin-mediated endocytosis, and chaperone-mediated stabilization—contribute to the dynamic control of ERBB2 activity in normal and pathological contexts. The intricate balance of these modifications ensures that ERBB2-mediated signaling is turned on only when appropriate, and aberrations in these regulatory mechanisms—such as overexpression and impaired degradation—are closely linked to oncogenic transformation (jr2004theerbbherreceptor pages 5-7, pinet2021expandingthedisorderfunction pages 16-17).

7. Function  
ERBB2 serves as a central signaling hub that modulates critical cellular processes including proliferation, differentiation, and survival. Although it does not bind a ligand directly, ERBB2 functions as an essential coreceptor within the neuregulin receptor complex by forming heterodimers with other ligand-responsive ErbB family members, particularly HER3. The formation of these heterodimers leads to robust activation of intracellular signaling cascades, most notably the PI3K/AKT and Ras/MAPK pathways, which are critical for promoting cell growth and protecting cells from apoptosis (bose2006phosphoproteomicanalysisof pages 1-1, collins2019preclinicalcharacteristicsof pages 13-15).  
Beyond its well‐documented roles in mitogenic and survival signaling, ERBB2 has a specialized function in the regulation of cytoskeletal dynamics. Activation of ERBB2 triggers the MEMO1-RHOA-DIAPH1 signaling cascade, culminating in the phosphorylation—and subsequent inhibition—of GSK3B at the cell membrane. This inhibition prevents GSK3B-mediated phosphorylation of downstream effectors, specifically APC and CLASP2, thereby permitting their association with the cell cortex. The membrane localization of APC in turn facilitates the recruitment of MACF1, a critical factor required for the capture and stabilization of peripheral microtubules. Consequently, ERBB2 plays a key role in the outgrowth and stabilization of microtubules, which is essential for maintaining cell polarity and directional motility (Information section).  
In addition to its roles in normal cell physiology, ERBB2 is best recognized for its oncogenic potential. Overexpression or gene amplification of ERBB2 is observed in approximately 20–30% of breast cancers and is associated with aggressive tumor progression and poor clinical outcomes (butti2018receptortyrosinekinases pages 1-3, collins2019preclinicalcharacteristicsof pages 15-17). In these contexts, the hyperactive receptor drives the continuous activation of survival and proliferation pathways, rendering tumor cells less responsive to conventional therapy while contributing to resistance mechanisms. As such, ERBB2 is one of the most important biomarkers and therapeutic targets in oncology, with its inhibition resulting in substantial clinical benefits across multiple studies (rochette2015anthracyclinestrastuzumabnewaspects pages 10-13).

8. Other Comments  
Clinically, ERBB2’s critical role in tumorigenesis has led to the development of several targeted therapeutic agents. Monoclonal antibodies such as trastuzumab (Herceptin) and pertuzumab are used to block receptor dimerization and to promote antibody‐dependent cellular cytotoxicity (ADCC), while small molecule tyrosine kinase inhibitors such as lapatinib and neratinib have been designed to inhibit the kinase activity by targeting the ATP binding pocket (rochette2015anthracyclinestrastuzumabnewaspects pages 10-13, collins2019preclinicalcharacteristicsof pages 5-7). Recent studies have also demonstrated that modulators like prolidase (PEPD) can act as natural ligands that bind to specific subdomains of the ERBB2 extracellular domain, leading to receptor internalization and degradation; this finding introduces potential novel approaches for modulating ERBB2 signaling (yang2014identificationofprolidase pages 6-7, yang2014identificationofprolidase pages 5-6).  
ERBB2 is not only a target in breast cancer but is also implicated in other malignancies where dysregulated receptor activity leads to aberrant signaling and oncogenesis. Ongoing research continues to address resistance mechanisms that arise through mutations in the kinase domain or compensatory activation of parallel signaling pathways, emphasizing the need for next-generation inhibitors that can overcome such challenges (collins2019preclinicalcharacteristicsof pages 11-13, collins2019preclinicalcharacteristicsof pages 13-15). Additionally, its involvement in the regulation of microtubule dynamics positions ERBB2 as a multifunctional protein whose signaling extends beyond classical growth factor pathways, potentially impacting cell migration and invasion. These multifaceted roles underscore the clinical significance of ERBB2 as both a biomarker and a therapeutic target.

9. References  
[1] Bose, R., Molina, H., Patterson, A. S., Bitok, J. K., Periaswamy, B., Bader, J. S., Pandey, A., & Cole, P. A. “Phosphoproteomic analysis of HER2/neu signaling and inhibition.” Proceedings of the National Academy of Sciences, 103:9773–9778, Jun 2006. (bose2006phosphoproteomicanalysisof pages 1-1, bose2006phosphoproteomicanalysisof pages 1-3)  
[2] Butti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. “Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.” Molecular Cancer, Feb 2018. (butti2018receptortyrosinekinases pages 17-18, butti2018receptortyrosinekinases pages 1-3, butti2018receptortyrosinekinases pages 7-9, butti2018receptortyrosinekinases pages 3-4, butti2018receptortyrosinekinases pages 18-18)  
[3] Collins, D., Conlon, N., Kannan, S., Verma, C., Eli, L., Lalani, A., & Crown, J. “Preclinical characteristics of the irreversible pan‐HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2‐positive and HER2‐mutated breast cancer.” Cancers, May 2019. (collins2019preclinicalcharacteristicsof pages 2-5, collins2019preclinicalcharacteristicsof pages 5-7, collins2019preclinicalcharacteristicsof pages 11-13, collins2019preclinicalcharacteristicsof pages 13-15, collins2019preclinicalcharacteristicsof pages 15-17, collins2019preclinicalcharacteristicsof pages 19-21, collins2019preclinicalcharacteristicsof pages 21-22, collins2019preclinicalcharacteristicsof pages 22-24, collins2019preclinicalcharacteristicsof pages 24-25)  
[4] Roskoski, R. Jr. “The ErbB/HER receptor protein-tyrosine kinases and cancer.” Biochemical and Biophysical Research Communications, 319:1–11, Jun 2004. (jr2004theerbbherreceptor pages 1-2, jr2004theerbbherreceptor pages 4-5, jr2004theerbbherreceptor pages 5-7, jr2004theerbbherreceptor pages 7-8, jr2004theerbbherreceptor pages 9-10)  
[5] Lucci, M. A., Orlandi, R., Triulzi, T., Tagliabue, E., Balsari, A., & Villa-Moruzzi, E. “Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.” Cellular Oncology, 32:361–372, Apr 2010. (lucci2010expressionprofileof pages 9-11, lucci2010expressionprofileof pages 11-12)  
[6] Mikulicic, S., Shamun, M., Massenberg, A., Franke, A.-L., Freitag, K., Döring, T., Strunk, J., Tenzer, S., Lang, T., & Florin, L. “ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity.” Frontiers in Immunology, Feb 2024. (mikulicic2024erbb2her2receptortyrosine pages 1-2)  
[7] Pinet, L., Assrir, N., & van Heijenoort, C. “Expanding the disorder-function paradigm in the C-terminal tails of ErbBs.” Biomolecules, 11:1690, Nov 2021. (pinet2021expandingthedisorderfunction pages 1-3, pinet2021expandingthedisorderfunction pages 3-5, pinet2021expandingthedisorderfunction pages 9-11, pinet2021expandingthedisorderfunction pages 16-17, pinet2021expandingthedisorderfunction pages 17-19, pinet2021expandingthedisorderfunction pages 20-21)  
[8] Rauch, J., Volinsky, N., Romano, D., & Kolch, W. “The secret life of kinases: functions beyond catalysis.” Cell Communication and Signaling, 9:23, Oct 2011. (rauch2011thesecretlife pages 1-2)  
[9] Rochette, L., Guenancia, C., Gudjoncik, A., Hachet, O., Zeller, M., Cottin, Y., & Vergely, C. “Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.” Trends in Pharmacological Sciences, 36:326–348, Jun 2015. (rochette2015anthracyclinestrastuzumabnewaspects pages 10-13, rochette2015anthracyclinestrastuzumabnewaspects pages 35-37)  
[10] Yang, L., Li, Y., & Zhang, Y. “Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth.” Cell Death & Disease, 5:e1211, May 2014. (yang2014identificationofprolidase pages 5-6, yang2014identificationofprolidase pages 6-7, yang2014identificationofprolidase pages 8-9, yang2014identificationofprolidase pages 9-9)  
[11] Riese, D. J., & Stern, D. F. “Specificity within the EGF family/ErbB receptor family signaling network.” BioEssays, 20:41–48, Dec 1998. (riese1998specificitywithinthe pages 2-4, riese1998specificitywithinthe pages 8-8)  
[12] Zhang, N., & Li, Y. “Receptor tyrosine kinases: biological functions and anticancer targeted therapy.” MedComm, Dec 2023. (zhang2023receptortyrosinekinases pages 1-2)  
[13] Johnson, L. N. “Protein kinase inhibitors: contributions from structure to clinical compounds.” Quarterly Reviews of Biophysics, 42:1–40, Feb 2009. (johnson2009proteinkinaseinhibitors pages 15-17)

References

1. (bose2006phosphoproteomicanalysisof pages 1-1): Ron Bose, Henrik Molina, A. Scott Patterson, John K. Bitok, Balamurugan Periaswamy, Joel S. Bader, Akhilesh Pandey, and Philip A. Cole. Phosphoproteomic analysis of her2/neu signaling and inhibition. Proceedings of the National Academy of Sciences, 103:9773-9778, Jun 2006. URL: https://doi.org/10.1073/pnas.0603948103, doi:10.1073/pnas.0603948103. This article has 258 citations.

2. (butti2018receptortyrosinekinases pages 17-18): Ramesh Butti, Sumit Das, Vinoth Prasanna Gunasekaran, Amit Singh Yadav, Dhiraj Kumar, and Gopal C. Kundu. Receptor tyrosine kinases (rtks) in breast cancer: signaling, therapeutic implications and challenges. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0797-x, doi:10.1186/s12943-018-0797-x. This article has 399 citations and is from a highest quality peer-reviewed journal.

3. (collins2019preclinicalcharacteristicsof pages 11-13): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

4. (collins2019preclinicalcharacteristicsof pages 19-21): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

5. (collins2019preclinicalcharacteristicsof pages 2-5): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

6. (collins2019preclinicalcharacteristicsof pages 21-22): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

7. (collins2019preclinicalcharacteristicsof pages 22-24): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

8. (jr2004theerbbherreceptor pages 1-2): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.

9. (jr2004theerbbherreceptor pages 4-5): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.

10. (jr2004theerbbherreceptor pages 5-7): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.

11. (jr2004theerbbherreceptor pages 9-10): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.

12. (lucci2010expressionprofileof pages 9-11): Maria Antonietta Lucci, R. Orlandi, T. Triulzi, E. Tagliabue, A. Balsari, and E. Villa-Moruzzi. Expression profile of tyrosine phosphatases in her2 breast cancer cells and tumors. Cellular Oncology : the Official Journal of the International Society for Cellular Oncology, 32:361-372, Apr 2010. URL: https://doi.org/10.3233/clo-2010-0520, doi:10.3233/clo-2010-0520. This article has 94 citations.

13. (mikulicic2024erbb2her2receptortyrosine pages 1-2): Snježana Mikuličić, Merha Shamun, Annika Massenberg, Anna-Lena Franke, Kirsten Freitag, Tatjana Döring, Johannes Strunk, Stefan Tenzer, Thorsten Lang, and Luise Florin. Erbb2/her2 receptor tyrosine kinase regulates human papillomavirus promoter activity. Frontiers in Immunology, Feb 2024. URL: https://doi.org/10.3389/fimmu.2024.1335302, doi:10.3389/fimmu.2024.1335302. This article has 3 citations and is from a peer-reviewed journal.

14. (pinet2021expandingthedisorderfunction pages 1-3): Louise Pinet, Nadine Assrir, and Carine van Heijenoort. Expanding the disorder-function paradigm in the c-terminal tails of erbbs. Biomolecules, 11:1690, Nov 2021. URL: https://doi.org/10.3390/biom11111690, doi:10.3390/biom11111690. This article has 6 citations and is from a peer-reviewed journal.

15. (pinet2021expandingthedisorderfunction pages 17-19): Louise Pinet, Nadine Assrir, and Carine van Heijenoort. Expanding the disorder-function paradigm in the c-terminal tails of erbbs. Biomolecules, 11:1690, Nov 2021. URL: https://doi.org/10.3390/biom11111690, doi:10.3390/biom11111690. This article has 6 citations and is from a peer-reviewed journal.

16. (rauch2011thesecretlife pages 1-2): Jens Rauch, Natalia Volinsky, David Romano, and Walter Kolch. The secret life of kinases: functions beyond catalysis. Cell Communication and Signaling : CCS, 9:23-23, Oct 2011. URL: https://doi.org/10.1186/1478-811x-9-23, doi:10.1186/1478-811x-9-23. This article has 243 citations.

17. (rochette2015anthracyclinestrastuzumabnewaspects pages 10-13): Luc Rochette, Charles Guenancia, Aurélie Gudjoncik, Olivier Hachet, Marianne Zeller, Yves Cottin, and Catherine Vergely. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends in Pharmacological Sciences, 36:326-348, Jun 2015. URL: https://doi.org/10.1016/j.tips.2015.03.005, doi:10.1016/j.tips.2015.03.005. This article has 307 citations and is from a highest quality peer-reviewed journal.

18. (rochette2015anthracyclinestrastuzumabnewaspects pages 35-37): Luc Rochette, Charles Guenancia, Aurélie Gudjoncik, Olivier Hachet, Marianne Zeller, Yves Cottin, and Catherine Vergely. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends in Pharmacological Sciences, 36:326-348, Jun 2015. URL: https://doi.org/10.1016/j.tips.2015.03.005, doi:10.1016/j.tips.2015.03.005. This article has 307 citations and is from a highest quality peer-reviewed journal.

19. (yang2014identificationofprolidase pages 6-7): Lu Yang, Y. Li, and Y. Zhang. Identification of prolidase as a high affinity ligand of the erbb2 receptor and its regulation of erbb2 signaling and cell growth. Cell Death &amp; Disease, 5:e1211-e1211, May 2014. URL: https://doi.org/10.1038/cddis.2014.187, doi:10.1038/cddis.2014.187. This article has 35 citations.

20. (bose2006phosphoproteomicanalysisof pages 1-3): Ron Bose, Henrik Molina, A. Scott Patterson, John K. Bitok, Balamurugan Periaswamy, Joel S. Bader, Akhilesh Pandey, and Philip A. Cole. Phosphoproteomic analysis of her2/neu signaling and inhibition. Proceedings of the National Academy of Sciences, 103:9773-9778, Jun 2006. URL: https://doi.org/10.1073/pnas.0603948103, doi:10.1073/pnas.0603948103. This article has 258 citations.

21. (butti2018receptortyrosinekinases pages 1-3): Ramesh Butti, Sumit Das, Vinoth Prasanna Gunasekaran, Amit Singh Yadav, Dhiraj Kumar, and Gopal C. Kundu. Receptor tyrosine kinases (rtks) in breast cancer: signaling, therapeutic implications and challenges. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0797-x, doi:10.1186/s12943-018-0797-x. This article has 399 citations and is from a highest quality peer-reviewed journal.

22. (butti2018receptortyrosinekinases pages 7-9): Ramesh Butti, Sumit Das, Vinoth Prasanna Gunasekaran, Amit Singh Yadav, Dhiraj Kumar, and Gopal C. Kundu. Receptor tyrosine kinases (rtks) in breast cancer: signaling, therapeutic implications and challenges. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0797-x, doi:10.1186/s12943-018-0797-x. This article has 399 citations and is from a highest quality peer-reviewed journal.

23. (collins2019preclinicalcharacteristicsof pages 13-15): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

24. (collins2019preclinicalcharacteristicsof pages 15-17): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

25. (collins2019preclinicalcharacteristicsof pages 24-25): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

26. (collins2019preclinicalcharacteristicsof pages 5-7): D. Collins, N. Conlon, S. Kannan, C. Verma, L. Eli, A. Lalani, and J. Crown. Preclinical characteristics of the irreversible pan-her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2-positive and her2-mutated breast cancer. Cancers, May 2019. URL: https://doi.org/10.3390/cancers11060737, doi:10.3390/cancers11060737. This article has 117 citations and is from a peer-reviewed journal.

27. (johnson2009proteinkinaseinhibitors pages 15-17): Louise N. Johnson. Protein kinase inhibitors: contributions from structure to clinical compounds. Quarterly Reviews of Biophysics, 42:1-40, Feb 2009. URL: https://doi.org/10.1017/s0033583508004745, doi:10.1017/s0033583508004745. This article has 333 citations and is from a peer-reviewed journal.

28. (jr2004theerbbherreceptor pages 7-8): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.

29. (lucci2010expressionprofileof pages 11-12): Maria Antonietta Lucci, R. Orlandi, T. Triulzi, E. Tagliabue, A. Balsari, and E. Villa-Moruzzi. Expression profile of tyrosine phosphatases in her2 breast cancer cells and tumors. Cellular Oncology : the Official Journal of the International Society for Cellular Oncology, 32:361-372, Apr 2010. URL: https://doi.org/10.3233/clo-2010-0520, doi:10.3233/clo-2010-0520. This article has 94 citations.

30. (pinet2021expandingthedisorderfunction pages 16-17): Louise Pinet, Nadine Assrir, and Carine van Heijenoort. Expanding the disorder-function paradigm in the c-terminal tails of erbbs. Biomolecules, 11:1690, Nov 2021. URL: https://doi.org/10.3390/biom11111690, doi:10.3390/biom11111690. This article has 6 citations and is from a peer-reviewed journal.

31. (pinet2021expandingthedisorderfunction pages 20-21): Louise Pinet, Nadine Assrir, and Carine van Heijenoort. Expanding the disorder-function paradigm in the c-terminal tails of erbbs. Biomolecules, 11:1690, Nov 2021. URL: https://doi.org/10.3390/biom11111690, doi:10.3390/biom11111690. This article has 6 citations and is from a peer-reviewed journal.

32. (pinet2021expandingthedisorderfunction pages 3-5): Louise Pinet, Nadine Assrir, and Carine van Heijenoort. Expanding the disorder-function paradigm in the c-terminal tails of erbbs. Biomolecules, 11:1690, Nov 2021. URL: https://doi.org/10.3390/biom11111690, doi:10.3390/biom11111690. This article has 6 citations and is from a peer-reviewed journal.

33. (pinet2021expandingthedisorderfunction pages 9-11): Louise Pinet, Nadine Assrir, and Carine van Heijenoort. Expanding the disorder-function paradigm in the c-terminal tails of erbbs. Biomolecules, 11:1690, Nov 2021. URL: https://doi.org/10.3390/biom11111690, doi:10.3390/biom11111690. This article has 6 citations and is from a peer-reviewed journal.

34. (riese1998specificitywithinthe pages 2-4): David J. Riese and David F. Stern. Specificity within the egf family/erbb receptor family signaling network. BioEssays, 20:41-48, Dec 1998. URL: https://doi.org/10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v, doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v. This article has 1148 citations and is from a peer-reviewed journal.

35. (riese1998specificitywithinthe pages 8-8): David J. Riese and David F. Stern. Specificity within the egf family/erbb receptor family signaling network. BioEssays, 20:41-48, Dec 1998. URL: https://doi.org/10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v, doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v. This article has 1148 citations and is from a peer-reviewed journal.

36. (yang2014identificationofprolidase pages 5-6): Lu Yang, Y. Li, and Y. Zhang. Identification of prolidase as a high affinity ligand of the erbb2 receptor and its regulation of erbb2 signaling and cell growth. Cell Death &amp; Disease, 5:e1211-e1211, May 2014. URL: https://doi.org/10.1038/cddis.2014.187, doi:10.1038/cddis.2014.187. This article has 35 citations.

37. (yang2014identificationofprolidase pages 8-9): Lu Yang, Y. Li, and Y. Zhang. Identification of prolidase as a high affinity ligand of the erbb2 receptor and its regulation of erbb2 signaling and cell growth. Cell Death &amp; Disease, 5:e1211-e1211, May 2014. URL: https://doi.org/10.1038/cddis.2014.187, doi:10.1038/cddis.2014.187. This article has 35 citations.

38. (yang2014identificationofprolidase pages 9-9): Lu Yang, Y. Li, and Y. Zhang. Identification of prolidase as a high affinity ligand of the erbb2 receptor and its regulation of erbb2 signaling and cell growth. Cell Death &amp; Disease, 5:e1211-e1211, May 2014. URL: https://doi.org/10.1038/cddis.2014.187, doi:10.1038/cddis.2014.187. This article has 35 citations.

39. (zhang2023receptortyrosinekinases pages 1-2): Nan Zhang and Yongsheng Li. Receptor tyrosine kinases: biological functions and anticancer targeted therapy. MedComm, Dec 2023. URL: https://doi.org/10.1002/mco2.446, doi:10.1002/mco2.446. This article has 28 citations.

40. (butti2018receptortyrosinekinases pages 18-18): Ramesh Butti, Sumit Das, Vinoth Prasanna Gunasekaran, Amit Singh Yadav, Dhiraj Kumar, and Gopal C. Kundu. Receptor tyrosine kinases (rtks) in breast cancer: signaling, therapeutic implications and challenges. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0797-x, doi:10.1186/s12943-018-0797-x. This article has 399 citations and is from a highest quality peer-reviewed journal.

41. (butti2018receptortyrosinekinases pages 3-4): Ramesh Butti, Sumit Das, Vinoth Prasanna Gunasekaran, Amit Singh Yadav, Dhiraj Kumar, and Gopal C. Kundu. Receptor tyrosine kinases (rtks) in breast cancer: signaling, therapeutic implications and challenges. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0797-x, doi:10.1186/s12943-018-0797-x. This article has 399 citations and is from a highest quality peer-reviewed journal.